資源描述：
《替吉奧聯合多西他賽和順鉑治療進展期胃癌的臨床觀察》由會員上傳分享，免費在線閱讀，更多相關內容在工程資料-天天文庫。
1、替吉奧聯合多西他賽和順鉑治療進展期胃癌的臨床觀察邱國欽，許麗貞，林智才，陳玉強摘要目的：觀察國產替吉奧聯合多西他賽和順鉑（DCS方案）一線治療進展期胃癌的有效性及安全性。方法：治療組24例進展期胃癌患者采用DCS方案化療；以同期采用多西他賽、順鉑、亞葉酸鈣及氟尿嘧啶方案（DCF方案）化療的24例進展期胃癌患者為對照組；至少3個周期后評價療效及不良反應。結果：48例均可評價；治療組的近期有效率（RR）為83.3%，優(yōu)于對照組的54.2%，差異有統(tǒng)計學意義（P＜0.05）；治療組中位TTP和MST分別為7.5個月和12.1個月，均高于對照組的5.6個月和8.4個月；治療
2、組的不良反應及嚴重反應發(fā)生率均明顯低于對照組（P＜0.05）。結論：國產替吉奧聯合多西他賽和順鉑化療方案一線治療進展期胃癌療效確切，不良反應較少，患者耐受性良好。關鍵詞進展期胃癌；化學治療；替吉奧；多西他賽；順鉑中圖分類號：R730.53；R735.2文獻標識碼：AClinicalobservationofS-1combinedwithDocetaxelandCisplatininthetreatmentofpatientswithadvancedgastriccarcinomaQIUGuo-qin，XULi-zhen，LINZhi-cai，CHENYu-qiang
3、.DepartmetofOncology,ChenggongHospitalAffiliatedtoXiamenUniversity,the174HospitalofPeople'sLiberationArmy.Xiamen361003ChinaAbstractObjective:ToevaluatetheeffectivenessandsafetyofthecombinationofS-1andDocetaxeltogetherwithCisplatin(DCStherapeuticregimens)inthetreatmentofpatientswithadva
4、ncedgastriccarcinoma.Methods：48patientswithadvancedgastriccarcinomawererandomlydividedintotwogroups.TheexperimentalgroupwastreatedbyDCStherapeuticschedules;thecontrolgroupwastreatedbyDoxtaxol,Cisplatin,CalciumFolinateand5-FU(DCFtherapeuticregimens).Short-termefficacyandadversereactions
5、wereevaluatedafterthreetreatmentcycles.Results:Allpatientscanbeevaluated.Thetumorresponserate(RR)oftheexperimentalgroupandthecontrolgroupinthisstudywas83.3%and54.2%,8respectively.Thedifferencebetweentwogroupswasstatisticalsignificant(P<0.05).Intheexperimentalgroup,mediantimetoprogressi
6、on(MTTP)andmediansurvivaltime(MST)were7.5monthsand12.1months,whileMTTPandMSTinthecontrolgroupwere5.6monthsand8.4months,respectively.Inaddition,comparedtothecontrolgroup,theexperimentalgroup’soccurrencerateofadversereactionsandseriousresponsewereapparentlylower(P<0.05).Conclusions:TheDC
7、Stherapeuticregimensshoweddefinitecurativeeffectinthetreatmentofpatientswithadvancedgastriccarcinoma,andtheadversereactionwasrelativelymildandtolerable.KeywordsAdvancedgastriccarcinoma;Chemotherapy;S-1;Docetaxel;Cisplatin進展期胃癌（advancedgastriccancer，AGC）又稱中、晚期胃癌，占整個胃癌發(fā)病率的60%~80%，多伴有淋巴
